Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anisodine hydrobromide injection for ischemic optic neuropathy
ChiCTR-IPR-16008021Phase 4Recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of anisodine in ischemic optic atrophy (IOA) (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoint: Total effective rate of disease. Started Dec 2015; status: recruiting.
02
Drugs
anisodine
03
Conditions
ischemic optic atrophy (IOA)
Beyond the preview
Go deeper on ChiCTR-IPR-16008021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16008021.